Imfinzi is the first immunotherapy cleared in the U.S. to treat muscle-invasive bladder cancer patients before and after bladder removal surgery, making for a new treatment option in a disease with high rates of recurrence. More: AstraZeneca bulks up Imfinzi's
read moreThe FDA has accepted Novo Nordisk’s application for a label expansion for oral GLP-1 treatment Rybelsus to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney
read moreNearly a year after a jury decided that Johnson & Johnson should be fined just over $150 million in a lawsuit alleging that the company engaged in misleading marketing tactics for two of its HIV meds, a judge has upped
read moreIn resigning as director of the FDA’s Center for Biologics Evaluation and Research, Peter Marks, M.D., Ph.D., blasted the promotion of vaccine disinformation under new HHS Secretary Robert F. Kennedy Jr. More: As FDA's Peter Marks resigns, industry watchers size
read moreMerck revealed data from a phase 3 study of pulmonary arterial hypertension drug Winrevair, which showed it reduced the risk of all-cause death, lung transplantation and hospitalization by 76% versus placebo, despite maximal background therapy. More: Merck's Winrevair slashes mortality-morbidity
read moreA rival bidder has emerged to acquire struggling gene therapy specialist bluebird bio, and the company’s board is “carefully reviewing” the offer, which values the biotech 50% higher than the original deal. More: Bluebird bio receives rival M&A bid worth
read more© 1994 - 2025 B.M. Pharmaceuticals